A long-lasting, complete hematologic and cytogenetic remission of chronic myelogenous leukemia after treatment with busulfan alone

被引：2
|
作者：
Mandigers, CMPW
Mensink, EJBM
van Kessel, AG
van der Plas, DC
Haanen, C
Hagemeÿer, A
de Witte, T
机构：
[1] Univ Nijmegen Hosp, Dept Hematol 544, NL-6500 HB Nijmegen, Netherlands
[2] Univ Nijmegen Hosp, Dept Anthropogenet, NL-6500 HB Nijmegen, Netherlands
[3] Erasmus Univ, Dept Cell Biol & Genet, NL-3000 DR Rotterdam, Netherlands
来源：
ANNALS OF HEMATOLOGY | 1996年 / 72卷 / 06期
关键词：
busulfan; chronic myelogenous leukemia; cytogenetic; minimal residual disease; polymerase chain reaction;
D O I：
10.1007/s002770050188
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A 44-year-old man suffering from cytogenetically and molecularly proven Philadelphia translocation-positive chronic myelogenous leukemia in chronic phase was treated with busulfan for 18 months and studied during a follow-up period of 13 years. Hematologically and cytogenetically, he attained a continuing complete remission, although at one point (9.5 years) at least, after attaining complete remission molecular analysis indicated the presence of minimal residual disease.
引用
收藏
页码：371 / 373
页数：3
相关论文
共 50 条
  • [21] HEMATOLOGIC AND CYTOGENETIC REMISSION OF BLASTIC TRANSFORMATION IN CHRONIC GRANULOCYTIC LEUKEMIA
    CANELLOS, GP
    DEVITA, VT
    WHANGPEN.J
    CARBONE, PP
    BLOOD-THE JOURNAL OF HEMATOLOGY, 1971, 38 (06): : 671 - +
  • [22] A BRAF-Negative Classic Hairy Cell Leukemia Patient with Long-Lasting Complete Remission after Rituximab and Pentostatin
    Gozzetti, Alessandro
    Sammartano, Vincenzo
    Bacchiarri, Francesca
    Raspadori, Donatella
    Bocchia, Monica
    TURKISH JOURNAL OF HEMATOLOGY, 2020, 37 (04) : 286 - 287
  • [23] HYDROXYUREA VERSUS BUSULFAN IN THE TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA
    RUSHING, D
    GOLDMAN, A
    GIBBS, G
    HOWE, R
    KENNEDY, BJ
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1982, 5 (03): : 307 - 313
  • [24] Rapid and long-lasting complete remission of a metastatic melanoma with pembrolizumab
    Messinger, L.
    Hauschild, A.
    Kahler, K.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 160 - 160
  • [25] Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
    Kantarjian, H
    Sawyers, C
    Hochhaus, A
    Guilhot, F
    Schiffer, C
    Gambacorti-Passerini, C
    Niederwieser, D
    Resta, D
    Capdeville, R
    Zoellner, U
    Talpaz, M
    Druker, B
    NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (09): : 645 - 652
  • [26] Sudden blastic transformation following complete cytogenetic (CG) remission (CCR) in chronic myelogenous leukemia (CML).
    Ravandi, F
    Cortes, J
    O'Brien, S
    Faderl, S
    Thomas, D
    Giles, F
    Talpaz, M
    Kantarjian, H
    BLOOD, 2000, 96 (11) : 738A - 739A
  • [27] Sequential transient novel chromosomal translocations in a patient with chronic myelogenous leukemia in complete cytogenetic remission after therapy with imatinib mesylate
    Papaioannou, George
    Athanasiadou, Anastasia
    Voutiadou, Georgia
    Gaitatzi, Maria
    Batsis, Ioannis
    Touloumenidou, Tasoula
    Anagnostopoulos, Achilles
    CANCER GENETICS, 2011, 204 (12) : 692 - 693
  • [28] Detection of BCR/ABL kinase domain mutations in chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib treatment.
    Chu, S
    Snyder, DS
    Sawyers, C
    Forman, SJ
    Bhatia, R
    BLOOD, 2003, 102 (11) : 70A - 71A
  • [29] Restoration of cellular immune function in chronic myelogenous leukemia patients in complete cytogenetic remission with interferon-alpha treatment.
    Johnson, H
    Talpaz, M
    Bang-Ning, L
    Kantarjian, HM
    Reuben, JM
    BLOOD, 1999, 94 (10) : 532A - 532A
  • [30] Hematologic remission of chronic myelogenous leukemia after treatment with imatinib includes normalization of the red cell distribution width.
    Bessman, JD
    Montoya, M
    BLOOD, 2005, 106 (11) : 301B - 301B
12345